氙增强通气CT引导的功能肺回避放疗用于肺癌患者
这项2期试验评估氙增强通气CT引导的功能肺回避放疗能否降低肺癌根治性放化疗患者的放射性肺炎发生率。36例患者中观察到17%(6/36)的≥2级放射性肺炎,与30%历史对照相比差异有统计学意义(P=.040);功能肺回避计划较标准计划显著保护总通气肺并降低生物评估预测的≥2级放射性肺炎风险(P=.001)。
要点
- 氙增强通气CT引导的功能肺回避放疗在36例肺癌患者中观察到17%的≥2级放射性肺炎。
- 功能肺回避计划较标准计划显著保护总通气肺并降低预测≥2级放射性肺炎风险(P=.001)。
- 氙增强总功能肺容积与用力肺活量(P=.012)及第1秒用力呼气容积(P=.035)正相关。
核心结论
- 氙增强通气CT引导的功能肺回避放疗在临床实践中显示出可行性,其获益应在更广泛的多中心试验环境中评估。
研究设计与样本
- 2期试验,共评估36例接受根治性放化疗的肺癌患者,功能肺通气通过肺功能检查和氙增强通气CT测量。
- 为每例患者设计不考虑氙增强通气CT的标准计划(SP)和以氙增强通气CT为指导优化降低功能肺剂量的功能肺回避计划(fAP),在治疗计划系统中比较两计划的剂量学参数和生物评估预测的放射性肺炎风险。
- 所有患者均接受批准的fAP,主要终点为≥2级放射性肺炎发生率,次要终点为生存结局。
主要发现
- 观察到≥2级放射性肺炎发生率为17%(6/36例),与30%历史对照相比差异有统计学意义(P=.040)。
- 与标准计划相比,功能肺回避计划显著保护总通气肺,使治疗计划系统生物评估预测的≥2级放射性肺炎风险降低(P=.001)。
- 氙增强总功能肺容积与肺功能检查通气参数正相关:用力肺活量(P=.012)、第1秒用力呼气容积(P=.035),而与弥散功能参数无相关性。
- 中位随访15.2个月,1年局部控制率、远处失败无生存率和总生存率分别为88%、66%和91%。
- 中位局部控制和中位总生存未达到,中位远处失败无生存为24.0个月(95%CI 15.7-32.3个月)。
关键数值与推荐
- 研究假设为功能肺回避计划可将≥2级放射性肺炎发生率降至12%,而历史发生率为30%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出其获益应在更广泛的多中心试验环境中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This phase 2 trial aimed to determine whether xenon-enhanced ventilation computed tomography (XeCT)-guided functional-lung-avoidance radiation therapy could reduce the radiation pneumonitis (RP) rate in patients with lung cancer undergoing definitive chemoradiation therapy. METHODS AND MATERIALS: Functional lung ventilation was measured via pulmonary function testing (PFT) and XeCT. A standard plan (SP) without reference to XeCT and a functional-lung-avoidance plan (fAP) optimized for lowering the radiation dose to the functional lung at the guidance of XeCT were designed. Dosimetric parameters and predicted RP risks modeled by biological evaluation were compared between the 2 plans in a treatment planning system (TPS). All patients received the approved fAP. The primary endpoint was the rate of grade ≥2 RP, and the secondary endpoints were the survival outcomes. The study hypothesis was that fAP could reduce the rate of grade ≥2 RP to 12% compared with a 30% historical rate. RESULTS: Thirty-six patients were evaluated. Xenon-enhanced total functional lung volumes positively correlated with PFT ventilation parameters (forced vital capacity, P = .012; forced expiratory volume in 1 second, P = .035), whereas they were not correlated with the diffusion capacity parameter. We observed a 17% rate of grade ≥2 RP (6 of 36 patients), which was significantly different (P = .040) compared with the historical control. Compared with the SP, the fAP significantly spared the total ventilated lung, leading to a reduction in predicted grade ≥2 RP (P = .001) by TPS biological evaluation. The median follow-up was 15.2 months. The 1-year local control (LC), disseminated failure-free survival (DFFS), and overall survival (OS) rates were 88%, 66%, and 91%, respectively. The median LC and OS were not reached, and the median DFFS was 24.0 months (95% confidence interval, 15.7-32.3 months). CONCLUSIONS: This report of XeCT-guided functional-lung-avoidance radiation therapy provided evidence showing its feasibility in clinical practice. Its benefit should be assessed in a broader multicenter trial setting.
引用
- Huang YS, Chen JL, Lan HT, et al. Xenon-Enhanced Ventilation Computed Tomography for Functional Lung Avoidance Radiation Therapy in Patients With Lung Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 36029910. doi:10.1016/j.ijrobp.2022.07.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。